Exicure, Inc. closes additional $11.2 million in private financing to advance its gene regulatory and immunotherapeutic programs
Financing Brings Total Raised to $31.5 Million in Last 45 Days SKOKIE, Ill.–(BUSINESS WIRE)–Exicure, Inc., the pioneer in gene regulatory and immunotherapeutic drugs utilizing three-dimensional Spherical Nucleic Acid (SNA™) constructs, […]
To access this content, you must purchase 1 Year Health News Illinois Subscription or 1 Year Group Subscription - Up to 5 Users, or log in if you are a member.
